CareDx Precision Medicine Diagnostics Showcased in Over 30 Abstracts and 9 Oral Presentations at the 2026 American Transplant Congress
Growing body of evidence supports AlloSure® as a clinical endpoint for risk assessment, treatment response, and long-term graft outcomes
Data across kidney, heart, lung, and multi-organ transplantation; featuring new KOAR prognostic findings and ImmuneScape™ single cell and spatial transcriptomics rejection classification advances
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced its participation at the American Transplant Congress (ATC) 2026, taking place June 20–24 in Boston, Massachusetts.
Real-world clinical use and scientific advancements involving AlloSure® Kidney, AlloSure Plus, HistoMap® Kidney, HeartCare® (AlloMap® Heart and AlloSure® Heart), and AlloSure® Lung will be featured in more than 30 abstracts and 9 oral presentations that include data generated from studies at over 110 transplant centers across the United States. The data reflect the continued evolution of AlloSure dd-cfDNA from an emerging biomarker to a potential clinical endpoint, with studies now utilizing AlloSure to assess allograft injury, monitor treatment response, and evaluate long-term graft health in kidney transplantation.
